Seronegativity for type 1 antineuronal nuclear antibodies ('anti-hu') in subacute sensory neuronopathy patients without cancer

Colin H. Chalk, Vanda A. Lennon, J. Clarke Stevens, Anthony J. Windebank

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

We followed 21 patients with sensory neuronopathy without evidence of cancer for up to 23 years. All were seronegative for type 1 antineuronal nuclear antibodies (ANNA-1, also called “anti-Hu”). We additionally studied 67 seropositive patients with sensory neuronopathy or a related neurologic syndrome. Ninety-one percent of the seropositive patients had a small-cell lung carcinoma. One, with a normal chest x-ray, had been followed for 7 years for sensory neuronopathy of indeterminate cause before serologic testing for ANNA-1 led to the discovery of the tumor by CT. We conclude that ANNA-1 seropositivity in a patient with sensory neuronopathy is strong evidence for an underlying small-cell lung cancer.

Original languageEnglish (US)
Pages (from-to)2209-2211
Number of pages3
JournalNeurology
Volume43
Issue number11
DOIs
StatePublished - Nov 1993

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Seronegativity for type 1 antineuronal nuclear antibodies ('anti-hu') in subacute sensory neuronopathy patients without cancer'. Together they form a unique fingerprint.

Cite this